HOME >> BIOLOGY >> NEWS
Florida scientists find enzyme replacement restores muscle strength in mice with Pompe's disease

GAINESVILLE, Fla.---University of Florida researchers have successfully restored normal muscle function in animals with a rare and fatal form of muscular dystrophy using a new form of enzyme replacement therapy.

In laboratory experiments, two doses of the enzyme strengthened the legs of a small sample of young mice with a muscle-wasting condition called Pompe's disease, according to findings from a new UF study. The enzyme replacement, which was developed and produced by Oklahoma City-based Novazyme Pharmaceuticals, had no adverse effects in the mice and could be tested in people within the year. "This is the first evidence that treatment for this disease has led to a functional correction of muscle strength," said Dr. Barry Byrne an associate professor in the College of Medicine's departments of pediatrics, and molecular genetics and microbiology. "The findings are preliminary and there's still a lot of work to do, but we're very encouraged."

Byrne, who also co-directs UF's Powell Gene Therapy Center, presented the results Sunday at the Federation of American Societies for Experimental Biologies conference in Orlando.

Pompe's disease is a debilitating genetic condition that causes an enlarged heart and liver, severe muscle weakness, breathing difficulties and destruction of respiratory muscle function, which eventually results in ventilator dependence. It is caused by the body's inability to manufacture any of the enzyme acid alpha-glucosidase, or GAA, also commonly called acid maltase. Milder forms of the disease are caused by inadequate supplies of the enzyme. Infants with Pompe's disease often die before age 2. Without the enzyme, a storage form of sugars and starches known as glycogen accumulates in and destroys muscle cells throughout the body, particularly those of the heart and respiratory muscles.

Though acid maltase deficiency diseases are rare, afflicting about 70,000 people worldwide, the UF research could lead to new treatment
'"/>

Contact: Paula Rausch
prausch@vpha.health.ufl.edu
352-392-2755
University of Florida
3-Apr-2001


Page: 1 2 3

Related biology news :

1. Tracing genes, biologists show lizard migration is traced to Florida
2. Florida Tech earns $50,000 grant to create coral database
3. Florida frontier expedition
4. Florida Tech researchers win $912,700 grant for cell studies
5. Exploring the sights and sounds of a deepwater coral marine protected area off Florida
6. Black water turns the tide on Florida coral
7. UCF to host Florida Academy of Sciences meeting
8. Coral smothering green tide seaweed spreading on Florida reefs
9. University of Florida engineers probe shape memory alloy for better prostheses
10. Common bacteria kills elkhorn coral off Florida keys, says UGA research team
11. University of South Florida team conducts trial for HIV vaccine

Post Your Comments:
(Date:5/17/2013)... for Experimental Biology (FASEB) released a new analysis ... highlighting the devastating impact of sequestration on the nation,s ... a May 15th Senate Appropriations Committee hearing featuring NIH ... $1.6 billion cut the agency sustained in FY 2013 ... the scientific community." , According to data from ...
(Date:5/16/2013)... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for The Society for Developmental Biology (SDB) ... 16-20, 2013. These awards are meant to promote ... underrepresented groups into the mainstream of the basic ... young scientists at the SDB 2013 Annual Meeting. ...
(Date:5/16/2013)... Injectable nanoparticles developed at MIT may someday eliminate ... to constantly monitor their blood-sugar levels and inject ... to sense glucose levels in the body and ... thereby replacing the function of pancreatic islet cells, ... diabetes. Ultimately, this type of system could ensure ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3
(Date:5/20/2013)... , May 20, 2013 Pacific Biomarkers and ... solutions for developers of biosimilars at the 2013 ... Sheraton San Diego Hotel and Marina ... will have the opportunity to speak with company representatives ... Paths That Cross" on May 21 from 1-2 p.m. ...
(Date:5/20/2013)... 20, 2013 Cempra, Inc. (Nasdaq: CEMP), ... antibiotics to meet critical medical needs in the ... presented data at the American Thoracic Society International ... demonstrating the antibacterial and enhanced immunomodulatory activity ... 2 clinical trial in outpatients with community acquired ...
(Date:5/20/2013)... Pittsburgh, PA (PRWEB) May 20, 2013 ... the Allegheny General Hospital (AGH) Cardiovascular Institute ... of coronary artery disease (CAD) over the ... procedures such as balloon angioplasty and coronary artery stent ... will once again play a prominent role in the ...
(Date:5/20/2013)... May 20, 2013 On 25-28 July, ... – in Paris - the beautiful city of lights. ... "Personalized Medicine is revolutionizing the medical world. Understanding and ... is the hallmark of this transformation. Much of the ... from the epidemiologic studies of large cohorts that do ...
Breaking Biology Technology:Pacific Biomarkers and Clinigene International To Announce Laboratory Solutions for Developers of Biosimilars at 2013 AAPS/ National Biotechnology Conference 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2
Cached News: